<DOC>
<DOCNO>EP-0643701</DOCNO> 
<TEXT>
<INVENTION-TITLE>
BENZIMIDAZOLE-DERIVED COMPOUNDS, METHOD FOR PREPARING SAME, AND THERAPEUTICAL AND COSMETIC USES THEREOF
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K830	A61K800	C07D23500	C07F900	A61Q1910	A61K800	A61K31415	A61P2900	A61K811	C07D23512	A61K811	A61P2900	A61Q1700	A61Q1900	A61K314184	A61P3708	A61Q1910	A61K849	A61Q1900	A61Q1700	A61P3700	A61K314164	C07F96506	C07D23518	A61K31415	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	C07D	C07F	A61Q	A61K	A61K	A61P	A61K	C07D	A61K	A61P	A61Q	A61Q	A61K	A61P	A61Q	A61K	A61Q	A61Q	A61P	A61K	C07F	C07D	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K8	A61K8	C07D235	C07F9	A61Q19	A61K8	A61K31	A61P29	A61K8	C07D235	A61K8	A61P29	A61Q17	A61Q19	A61K31	A61P37	A61Q19	A61K8	A61Q19	A61Q17	A61P37	A61K31	C07F9	C07D235	A61K31	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
CT INTERNAT DE RECH S BR DERMA
</APPLICANT-NAME>
<APPLICANT-NAME>
CENTRE INTERNATIONAL DE RECHERCHES
<
BR
>
DERMATOLOGIQUES GALDERMA
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CAVEY DANIEL
</INVENTOR-NAME>
<INVENTOR-NAME>
ROCHER JEAN-PHILIPPE
</INVENTOR-NAME>
<INVENTOR-NAME>
CAVEY, DANIEL
</INVENTOR-NAME>
<INVENTOR-NAME>
ROCHER, JEAN-PHILIPPE
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Claims for the following Contracting States : AT, BE, CH, LI, DE, DK, FR, GB, IT, NL, SE
Benzimidazole derivatives, 
characterized in that

they correspond to the following general formula:


in which:

R
1
 and R
2
 represent a hydrogen atom, an alkyl
radical having from 1 to 6 carbon atoms, an OR
4

radical, a fluoroalkyl radical having from 1 to 6
carbon atoms and from 1 to 5 fluorine atoms or a

halogen atom,
R
3
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, a halogen, a

hydroxyl or a lower alkoxy radical having from 1
to 6 carbon atoms,
R
4
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, a benzyl radical

or a


PO
3
H or SO
3
H radical or an amino acid
residue,
R
7
 represents an alkyl radical having from 1 to 6 
carbon atoms, a lo
wer alkoxy radical having from 1
to 6 carbon atoms, the -(CH
2
)
n
-COOH, n = 1 to 6,
radical or the radical


r' and r" representing a hydrogen atom or an alkyl
radical having from 1 to 6 carbon atoms or r' and

r", taken together, forming, with the nitrogen
atom, a 5- or 6-membered heterocycle chosen from

the piperidino, morpholino, pyrrolidino or
piperazino radicals, the piperazino radical

optionally being substituted in the 4-position by
an alkyl radical having from 1 to 6 carbon atoms,
one of R
5
 and R
6
 represents an OR
8
 radical and the
other a mono- or polycyclic cycloalkyl radical

having from 5 to 12 carbon atoms which is bonded
to the phenyl nucleus via a tertiary carbon;
R
8
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, an acyl radical

having from 2 to 7 carbon atoms, a benzyl radical
optionally substituted by one or more halogen

atoms or the benzoyl radical;
and the salts of the said compounds obtained by
addition of a pharmaceutically acceptable acid or

base.
Compounds according to Claim 1, 
characterized in
that
 the alkyl radical having from 1 to 6 carbon
atoms is chosen from the methyl, ethyl, isopropyl,

butyl, 1-methylpropyl, 1-ethylpropyl, tert-butyl,
1,1-dimethylpropyl and l-methyl-l-ethylpropyl

radicals.
Compounds according to Claim 1, 
characterized in
that
 the fluoroalkyl radical having from 1 to 6
carbon atoms and from 1 to 5 fluorine atoms is 

preferably the trifluoromethyl radical
Compounds according to Claim 1, 
characterized in
that
 the halogen atom is chlorine, bromine or
fluorine.
Compounds according to Claim 1, 
characterized in
that
 the amino acid residue is a residue deriving
from lysine, glycine or aspartic acid.
Compounds according to Claim 1, 
characterized in
that
 the alkoxy radical is chosen from the
methoxy, ethoxy, isopropoxy and butoxy radicals.
Compounds according to Claim 1, 
characterized in
that
 the mono- or polycyclic cycloalkyl radical
having from 5 to 12 carbon atoms which is bonded

to the phenyl nucleus via a tertiary carbon is
chosen from the 1-adamantyl and 1-methylcyclohexyl

radicals.
Compounds according to Claim 1, 
characterized in
that
 the acyl radical having from 2 to 7 carbon
atoms is chosen from the acetyl, propionyl,

butyryl, isobutyryl, valeryl and pivaloyl
radicals.
Compounds according to any one of the preceding
claims, 
characterized in that
 they are taken from
the group consisting of:


4-hydroxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-hydroxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzi-midazole,
5-hydroxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-methylcyclohexyl)-4-benzyloxyphenyl]benzimidazole, 
5-hydroxy-2-[3-(1-methylcyclohexyl)-4-hydroxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-benzyloxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-benzyloxy-2-[3-benzyloxy-4-(1-adamantyl)phenyl]benzimidazole,
5-hydroxy-2-[3-hydroxy-4-(1-adamantyl)phenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-benzyloxy-5-methoxyphenyl]benzimidazole,
5-hydroxy-2-[3-(1-adamantyl)-4-hydroxy-5-methoxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-benzyloxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzimidazole,
5-acetoxy-2-[3-(1-adamantyl)-4-acetoxyphenyl]benzimidazole,
5-acetoxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole.
Process for the preparation of the compounds of
formula (I) according to any one of Claims 1 to 9

and their salts, in which an aromatic carboxylic
acid derivative of formula:



is reacted with an ortho-nitroaniline of formula: 


in which R
1
, R
2
 and R
4
 have the same meanings as
those given in Claim 1, Q represents a hydroxyl

functional group or a chlorine atom and Ar
represents the radical:



the reaction being carried out in pyridine, a
reduction reaction is subsequently carried out on

the intermediate compound obtained, then
cyclization is carried out by heating in a solvent

in the presence of a reactant chosen from paratoluenesulphonic
acid or phosphorus oxychloride

and, if desired, the salts of the said compounds
of formula I are prepared by addition of a

pharmaceutically acceptable acid or base.
Pharmaceutical composition, 
characterized in that

it comprises, in a vehicle appropriate for
enteral, parenteral, topical or ocular

administration, at least one compound of formula
(I) according to any one of Claims 1 to 9.
Composition according to Claim 11, 
characterized
in that
 it is provided in a form appropriate for
topical application and comprises from 0.005% to

10% by weight of the said compound. 
Use of a compound according to any one of Claims 1
to 9 for the preparation of a pharmaceutical

composition intended for the treatment or
prevention of inflammatory and/or immunoallergic

conditions.
Cosmetic composition intended to prevent an
unsightly appearance of the skin, 
characterized in
that
 it comprises, in an appropriate cosmetic
vehicle, at least one compound as defined in any

one of Claims 1 to 9.
Cosmetic composition according to Claim 14,

characterized in that
 it comprises the said
compound at a concentration of between 0.001 and

5% with respect to the total weight of the
composition.
Claims for the following Contracting State : ES
Process for the preparation of benzimidazole
derivatives of the general formula:



in which:

R
1
 and R
2
 represent a hydrogen atom, an alkyl
radical having from 1 to 6 carbon atoms, an OR
4

radical, a fluoroalkyl radical having from 1 to 6
carbon atoms and from 1 to 5 fluorine atoms or a

halogen atom,
R
3
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, a halogen, a

hydroxyl or a lower alkoxy radical having from 1
to 6 carbon atoms,
R
4
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, a benzyl radical

or a


PO
3
H or SO
3
H radical or an amino acid
residue,
R
7
 represents an alkyl radical having from 1 to 6
carbon atoms, a lower alkoxy radical having from 1 

to 6 carbon atoms the -(CH
2
)
n
-COOH, n = 1 to 6,
radical or the radical


r' and r" representing a hydrogen atom or an alkyl
radical having from 1 to 6 carbon atoms or r' and

r", taken together, forming, with the nitrogen
atom, a 5- or 6-membered heterocycle chosen from

the piperidino, morpholino, pyrrolidino or
piperazino radicals, the piperazino radical

optionally being substituted in the 4-position by
an alkyl radical having from 1 to 6 carbon atoms,
one of R
5
 and R
6
 represents an OR
8
 radical and the
other a mono- or polycyclic cycloalkyl radical

having from 5 to 12 carbon atoms which is bonded
to the phenyl nucleus via a tertiary carbon;
R
8
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, an acyl radical

having from 2 to 7 carbon atoms, a benzyl radical
optionally substituted by one or more halogen

atoms or the benzoyl radical;
and the salts of the said compounds, in which an
aromatic carboxylic acid derivative of formula:



is reacted with an ortho-nitroaniline of formula: 


in which R
1
, R
2
 and R
4
 are defined as above, Q
represents a hydroxyl functional group or a

chlorine atom and Ar represents the radical:


the reaction being carried out in pyridine, a
reduction reaction is subsequently carried out on

the intermediate compound obtained, then
cyclization is carried out by heating in a solvent

in the presence of a reactant chosen from paratoluenesulphonic
acid or phosphorus oxychloride

and, if desired, the salts of the said compounds
of formula I are prepared by addition of a

pharmaceutically acceptable acid or base.
Process according to Claim 1, 
characterized in
that
 the alkyl radical having from 1 to 6 carbon
atoms is chosen from the methyl, ethyl, isopropyl,

butyl, 1-methylpropyl, 1-ethylpropyl, tert-butyl,
1,1-dimethylpropyl and 1-methyl-l-ethylpropyl

radicals.
Process according to Claim 1, 
characterized in
that
 the fluoroalkyl radical having from 1 to 6
carbon atoms and from 1 to 5 fluorine atoms is

preferably the trifluoromethyl radical. 
Process according to Claim 1, 
characterized in
that
 the halogen atom is chlorine, bromine or
fluorine.
Process according to Claim 1, 
characterized in
that
 the amino acid residue is a residue deriving
from lysine, glycine or aspartic acid.
Process according to Claim 1, 
characterized in
that
 the alkoxy radical is chosen from the
methoxy, ethoxy, isopropoxy and butoxy radicals.
Process according to Claim 1, 
characterized in
that
 the mono- or polycyclic cycloalkyl radical
having from 5 to 12 carbon atoms which is bonded

to the phenyl nucleus via a tertiary carbon is
chosen from the 1-adamantyl and 1-methylcyclohexyl

radicals.
Process according to Claim 1, 
characterized in
that
 the acyl radical having from 2 to 7 carbon
atoms is chosen from the acetyl, propionyl,

butyryl, isobutyryl, valeryl and pivaloyl
radicals.
Process according to any one of the preceding
claims, 
characterized in that
 the said compound is
chosen from the group consisting of:


4-hydroxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-hydroxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzimidazole,
5-hydroxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-methylcyclohexyl)-4-benzyloxyphenyl]benzimidazole, 
5-hydroxy-2-[3-(1-methylcyclohexyl)-4-hydroxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-benzyloxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-benzyloxy-2-[3-benzyloxy-4-(1-adamantyl)phenyl]benzimidazole,
5-hydroxy-2-[3-hydroxy-4-(1-adamantyl)phenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-benzyloxy-5-methoxyphenyl]benzimidazole,
5-hydroxy-2-[3-(1-adamantyl)-4-hydroxy-5-methoxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-benzyloxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzimidazole,
5-acetoxy-2-[3-(1-adamantyl)-4-acetoxyphenyl]benzimidazole,
5-acetoxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole.
Process for the preparation of a pharmaceutical
composition, 
characterized in that
 at least one
compound which can be obtained according to the

process of any one of Claims 1 to 9 is mixed with
a vehicle appropriate for enteral, parenteral,

topical or ocular administration.
Process according to Claim 10, 
characterized in
that
 the composition obtained is provided in a
form appropriate for topical application and

comprises 0.005% to 10% by weight of the said
compound.
Process according to either one of Claims 10
and 11, in which the pharmaceutical composition

obtained is intended for the treatment or 
prevention of inflammatory and/or immunoallergic

conditions.
Cosmetic composition intended to prevent an
unsightly appearance of the skin, 
characterized in
that
 it comprises, in an appropriate cosmetic
vehicle, at least one compound which can be

obtained according to the process of any one of
Claims 1 to 9.
Cosmetic composition according to Claim 13,

characterized in that
 it comprises the said
compound at a concentration of between 0.001 and

5% with respect to the total weight of the
composition.
Claims for the following Contracting State : GR
Benzimidazole derivatives, 
characterized in that

they correspond to the following general formula:


in which:

R
1
 and R
2
 represent a hydrogen atom, an alkyl
radical having from 1 to 6 carbon atoms, an OR
4

radical, a fluoroalkyl radical having from 1 to 6
carbon atoms and from 1 to 5 fluorine atoms or a

halogen atom,
R
3
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, a halogen, a

hydroxyl or a lower alkoxy radical having from 1
to 6 carbon atoms,
R
4
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, a benzvl radical

or a


PO
3
H or SO
3
H radical or an amino acid
residue,
R
7
 represents an alkyl radical having from 1 to 6 
carbon atoms, a lower alkoxy radical having from 1

to 6 carbon atoms, the -(CH
2
)
n
-COOH, n = 1 to 6,
radical or the radical


r' and r" representing a hydrogen atom or an alkyl
radical having from 1 to 6 carbon atoms or r' and

r", taken together, forming, with the nitrogen
atom, a 5- or 6-membered heterocycle chosen from

the piperidino, morpholino, pyrrolidino or
piperazino radicals, the piperazino radical

optionally being substituted in the 4-position by
an alkyl radical having from 1 to 6 carbon atoms,
one of R
5
 and R
6
 represents an OR
8
 radical and the
other a mono- or polycyclic cycloalkyl radical

having from 5 to 12 carbon atoms which is bonded
to the phenyl nucleus via a tertiary carbon;
R
8
 represents a hydrogen atom, an alkyl radical
having from 1 to 6 carbon atoms, an acyl radical

having from 2 to 7 carbon atoms, a benzyl radical
optionally substituted by one or more halogen

atoms or the benzoyl radical;
and the salts of the said compounds obtained by
addition of a pharmaceutically acceptable acid or

base.
Compounds according to Claim 1, 
characterized in
that
 the alkyl radical having from 1 to 6 carbon
atoms is chosen from the methyl, ethyl, isopropyl,

butyl, 1-methylpropyl, 1-ethylpropyl, tert-butyl,
1,1-dimethylpropyl and 1-methyl-l-ethylpropyl

radicals.
Compounds according to Claim 1, 
characterized in
that
 the fluoroalkyl radical having from 1 to 6
carbon atoms and from 1 to 5 fluorine atoms is 

preferably the trifluoromethyl radical.
Compounds according to Claim 1, 
characterized in
that
 the halogen atom is chlorine, bromine or
fluorine.
Compounds according to Claim 1, 
characterized in
that
 the amino acid residue is a residue deriving
from lysine, glycine or aspartic acid.
Compounds according to Claim 1, 
characterized in
that
 the alkoxy radical is chosen from the
methoxy, ethoxy, isopropoxy and butoxy radicals.
Compounds according to Claim 1, 
characterized in
that
 the mono- or polycyclic cycloalkyl radical
having from 5 to 12 carbon atoms which is bonded

to the phenyl nucleus via a tertiary carbon is
chosen from the 1-adamantyl and 1-methylcyclohexyl

radicals.
Compounds according to Claim 1, 
characterized in
that
 the acyl radical having from 2 to 7 carbon
atoms is chosen from the acetyl, propionyl,

butyryl, isobutyryl, valeryl and pivaloyl
radicals.
Compounds according to any one of the preceding
claims, 
characterized in that
 they are taken from
the group consisting of:


4-hydroxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-hydroxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzimidazole,
5-hydroxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-methylcyclohexyl)-4-benzyloxyphenyl]benzimidazole, 
5-hydroxy-2-[3-(1-methylcyclohexyl)-4-hydroxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-benzyloxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole,
5-benzyloxy-2-[3-benzyloxy-4-(1-adamantyl)phenyl]benzimidazole,
5-hydroxy-2-[3-hydroxy-4-(1-adamantyl)phenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-benzyloxy-5-methoxyphenyl]benzimidazole,
5-hydroxy-2-[3-(1-adamantyl)-4-hydroxy-5-methoxyphenyl]benzimidazole,
5-benzyloxy-2-[3-(1-adamantyl)-4-benzyloxyphenyl]benzimidazole,
5-methoxy-2-[3-(1-adamantyl)-4-methoxyphenyl]benzimidazole,
5-acetoxy-2-[3-(1-adamantyl)-4-acetoxyphenyl]benzimidazole,
5-acetoxy-2-[3-(1-adamantyl)-4-hydroxyphenyl]benzimidazole.
Process for the preparation of the compounds of
formula (I) according to any one of Claims 1 to 9

and their salts, in which an aromatic carboxylic
acid derivative of formula:



is reacted with an ortho-nitroaniline of formula: 


in which R
1
, R
2
 and R
4
 have the same meanings as
those given in Claim 1, Q represents a hydroxyl

functional group or a chlorine atom and Ar
represents the radical:



the reaction being carried out in pyridine, a
reduction reaction is subsequently carried out on

the intermediate compound obtained, then
cyclization is carried out by heating in a solvent

in the presence of a reactant chosen from paratoluenesulphonic
acid or phosphorus oxychloride

and, if desired, the salts of the said compounds
of formula I are prepared by addition of a

pharmaceutically acceptable acid or base.
Process for the preparation of a pharmaceutical
composition, 
characterized in that
 at least one
compound which can be obtained according to the

process of Claim 10 is mixed with a vehicle
appropriate for enteral, parenteral, topical or

ocular administration.
Process according to Claim 11, 
characterized in
that
 the composition obtained is provided in a
form appropriate for topical application and 

comprises 0.005% to 10% by weight of the said
compound.
Process according to either one of Claims 11
and 12, in which the pharmaceutical composition

obtained is intended for the treatment or
prevention of inflammatory and/or immunoallergic

conditions.
Cosmetic composition intended to prevent an
unsightly appearance of the skin, 
characterized in
that
 it comprises, in an appropriate cosmetic
vehicle, at least one compound which can be

obtained according to the process of Claim 10.
Cosmetic composition according to Claim 14,

characterized in that
 it comprises the said
compound at a concentration of between 0.001 and

5% with respect to the total weight of the
composition.
</CLAIMS>
</TEXT>
</DOC>
